XyloCor doses patients in phase 1/2 trial evaluating XC001 in refractory angina

This article was originally published here

The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary intervention. XC001 is an investigational novel

The post XyloCor doses patients in phase 1/2 trial evaluating XC001 in refractory angina appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply